{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:10:53Z","timestamp":1778299853903,"version":"3.51.4"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.6887-25","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:10:40Z","timestamp":1777932640000},"source":"Crossref","is-referenced-by-count":0,"title":["A low guideline-directed medical therapy score is associated with adverse outcomes in patients with heart failure with a reduced ejection fraction and renal dysfunction"],"prefix":"10.2169","author":[{"given":"Makoto","family":"Kishihara","sequence":"first","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurika","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asaka","family":"Mikami","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arisa","family":"Nokubo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manami","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayano","family":"Yuasa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Shirotani","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiharu","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Shibahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Daimon","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Shiga","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"},{"name":"Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72: 351-366, 2018."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Janse RJ, Fu EL, Dahlstr\u00f6m U, et al. Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence. Eur J Heart Fail 24: 2185-2195, 2022.","DOI":"10.1002\/ejhf.2620"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shiga T, Suzuki A, Haruta S, et al. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. ESC Heart Fail 6: 475-486, 2019.","DOI":"10.1002\/ehf2.12418"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Heywood JT, Fonarow GC, Yancy CW, et al. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. Am J Cardiol 105: 1140-1146, 2010.","DOI":"10.1016\/j.amjcard.2009.12.016"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 118: 3272-3287, 2023.","DOI":"10.1093\/cvr\/cvac013"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. Card Fail Rev 9: e11, 2023.","DOI":"10.15420\/cfr.2023.05"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sato N. Critical issue in the cardiovascular field: hospitalization for heart failure. J Cardiol 62: 140-141, 2013.","DOI":"10.1016\/j.jjcc.2013.05.011"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. McDonagh TA, Metra M, Adamo M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24: 4-131, 2022.","DOI":"10.1002\/ejhf.2333"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145: e876-e894, 2022.","DOI":"10.1161\/CIR.0000000000001073"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kitai T, Kohsaka S, Kato T, et al. JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure. Circ J 89: 1278-1444, 2025.","DOI":"10.1253\/circj.CJ-25-0002"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Swedberg K, Komajda M, B\u00f6hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376: 875-885, 2010.","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382: 1883-1893, 2020.","DOI":"10.1056\/NEJMoa1915928"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. McCullough PA, Mehta HS, Barker CM, et al. Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction. Clin Cardiol 44: 1192-1198, 2021.","DOI":"10.1002\/clc.23664"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Matsukawa R, Okahara A, Tokutome M, et al. A scoring evaluation for the practical introduction of guideline-directed medical therapy in heart failure patients. ESC Heart Fail 10: 3352-3363, 2023.","DOI":"10.1002\/ehf2.14524"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Savarese G, Lindberg F, Christodorescu RM, et al. Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. a survey of the heart failure association of the ESC and the ESC council for cardiology practice. Eur J Heart Fail 26: 1408-1418, 2024.","DOI":"10.1002\/ejhf.3214"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ouwerkerk W, Voors AA, Anker SD, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38: 1883-1890, 2017.","DOI":"10.1093\/eurheartj\/ehx026"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Linde C, Bakhai A, Furuland H, et al. Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc 8: e012655, 2019.","DOI":"10.1161\/JAHA.119.012655"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tsukamoto K, Suzuki A, Shiga T, Arai K, Hagiwara N. Changes in the left ventricular ejection fraction and outcomes in hospitalized heart failure patients with mid-range ejection fraction: a prospective observational study. Intern Med 60: 1509-1518, 2021.","DOI":"10.2169\/internalmedicine.6388-20"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Haruki K, Suzuki A, Yoshida A, Ashihara K, Yamaguchi J, Shiga T. Persistently low tricuspid annular plane systolic excursion and its prognosis in Japanese hospitalized patients with heart failure with reduced ejection fraction. Heart Vessels 40: 391-404, 2025.","DOI":"10.1007\/s00380-024-02481-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Fiuzat M, Hamo CE, Butler J, et al. Optimal background pharmacological therapy for heart failure patients in clinical trials: JACC review topic of the week. J Am Coll Cardiol 79: 504-510, 2022.","DOI":"10.1016\/j.jacc.2021.11.033"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371: 993-1004, 2014.","DOI":"10.1056\/NEJMoa1409077"},{"key":"23","unstructured":"23. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381: 1995-2008, 2019."},{"key":"24","unstructured":"24. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383: 1413-1424, 2020."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 52: 1527-1539, 2008.","DOI":"10.1016\/j.jacc.2008.07.051"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Stolfo D, Sinagra G, Savarese G. Evidence-based therapy in older patients with heart failure with reduced ejection fraction. Card Fail Rev 8: e16, 2022.","DOI":"10.15420\/cfr.2021.34"},{"key":"27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.hroo.2024.01.004","volume":"5","author":"JL Mignone","year":"2024","unstructured":"27. Mignone JL, Alexander KM, Dobbles M, Eberst K, Fonarow GC, Ellenbogen KA. Outcomes with guideline-directed medical therapy and cardiac implantable electronic device therapies for patients with heart failure with reduced ejection fraction. Heart Rhythm 5: 168-173, 2024.","journal-title":"Heart Rhythm","ISSN":"https:\/\/id.crossref.org\/issn\/1547-5271","issn-type":"print"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Pitt B, Rossignol P. Impact of hyperkalemia and worsening renal function on the use of renin angiotensin aldosterone system inhibitors in chronic heart failure with reduced ejection fraction. Clin Pharmacol Ther 102: 389-391, 2017.","DOI":"10.1002\/cpt.746"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther 30: 233-239, 2005.","DOI":"10.1111\/j.1365-2710.2005.00638.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. DeFilippis EM, Desai AS. Treatment of hyperkalemia in heart failure. Curr Heart Fail Rep 14: 266-274, 2017.","DOI":"10.1007\/s11897-017-0341-0"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117-2128, 2015.","DOI":"10.1056\/NEJMoa1504720"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and Nephropathy. N Engl J Med 380: 2295-2306, 2019.","DOI":"10.1056\/NEJMoa1811744"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Nagara K, Suzuki A, Shiga T, Hagiwara N. Long-term outcome of carvedilol therapy in Japanese patients with nonischemic heart failure. Heart Vessels 35: 957-966, 2020.","DOI":"10.1007\/s00380-020-01560-w"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Chen X, Cui X, Thunstr\u00f6m E, Pivodic A, Dahlstr\u00f6m U, Fu M. Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction. Clin Res Cardiol 110: 1051-1062, 2021.","DOI":"10.1007\/s00392-020-01790-y"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Butler J, Gheorghiade M, Metra M. Moving away from symptoms-based heart failure treatment: misperceptions and real risks for patients with heart failure. Eur J Heart Fail 18: 350-352, 2016.","DOI":"10.1002\/ejhf.507"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_6887-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:32:16Z","timestamp":1778297536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_6887-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":35,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6887-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"6887-25"}}